Ignite Creation Date:
2025-12-24 @ 6:40 PM
Ignite Modification Date:
2026-01-01 @ 6:52 PM
Study NCT ID:
NCT00964457
Status:
UNKNOWN
Last Update Posted:
2009-08-25
First Post:
2009-08-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients
Sponsor:
Copenhagen University Hospital at Herlev
Organization:
Study Overview
Official Title:
Treatment of Patient With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before Under and After Radiation and With Adding Cetuximab to K_RAS Wild-type Patients.
Status:
UNKNOWN
Status Verified Date:
2009-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer
Detailed Description:
Dynamic MRI will be used to monitor the effect of the treatment and will be compared to pathologic results.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: